{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-056863","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.922819+00:00","generated_at":"2026-06-15T12:11:57.020580+00:00","sec_items":["7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics names Monic Stuart, M.D., as new CMO; she brings 20+ years drug development experience","bullets":["Dr. Stuart appointed CMO effective May 8, 2023; will oversee multiTAA-specific T cell pipeline including MT-401 Phase 2 ARTEMIS study.","Over 20 years experience; previously interim CMO at multiple biotechs, VP Clinical Development at Geron, Senior Medical Director at Genentech.","She is a transplant physician with expertise in AML and lymphoma, aligning with Marker's prioritized clinical programs.","Dr. Stuart will lead clinical strategy for MT-401 in AML and MT-601 in non-Hodgkin lymphoma and pancreatic cancer.","CEO Juan Vera cited her deep industry experience and clinical background as key to advancing pipeline."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-056863","json":"https://secwatch.observer/filing/0001104659-23-056863.json","markdown":"https://secwatch.observer/filing/0001104659-23-056863.md","text":"https://secwatch.observer/filing/0001104659-23-056863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923056863/0001104659-23-056863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465923056863/tm2314958d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:11:57.020580+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}